國立虎尾科技大學 |

Cancer II

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cancer II/ edited by Michael J. Waring.
其他作者:	Waring, Michael J.
面頁冊數:	XIV, 475 p. 150 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Medicinal chemistry. -
電子資源:	https://doi.org/10.1007/978-3-319-75926-5
ISBN:	9783319759265

Cancer II
Cancer II[electronic resource] /edited by Michael J. Waring. - 1st ed. 2018. - XIV, 475 p. 150 illus.online resource. - Topics in Medicinal Chemistry,281862-2461 ;. - Topics in Medicinal Chemistry,15.

Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia -- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor -- Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase -- Inhibitors of Vascular Endothelial Growth Factor Receptor -- Inhibitors of the Fibroblast Growth Factor Receptor -- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family -- Epigenetic Modulators -- Antibody–Drug Conjugates -- Isoform Selective PI3K Inhibitors for Treating Cancer -- Inhibitors of the Kynurenine Pathway -- Protein–Protein Interaction Inhibitors -- Small Molecule Inhibitors of ALK.

This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.

ISBN: 9783319759265

Standard No.: 10.1007/978-3-319-75926-5doiSubjects--Topical Terms:

1253747
Medicinal chemistry.

LC Class. No.: RS400-431

Dewey Class. No.: 615.19

Cancer II
LDR:02805nam a22003975i 4500 001 987298
003 DE-He213
005 20200706040737.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319759265 $9 978-3-319-75926-5
024 7 $a 10.1007/978-3-319-75926-5 $2 doi
035 $a 978-3-319-75926-5
050 4 $a RS400-431
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Cancer II $h [electronic resource] / $c edited by Michael J. Waring.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XIV, 475 p. 150 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 28
505 0 $a Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia -- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor -- Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase -- Inhibitors of Vascular Endothelial Growth Factor Receptor -- Inhibitors of the Fibroblast Growth Factor Receptor -- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family -- Epigenetic Modulators -- Antibody–Drug Conjugates -- Isoform Selective PI3K Inhibitors for Treating Cancer -- Inhibitors of the Kynurenine Pathway -- Protein–Protein Interaction Inhibitors -- Small Molecule Inhibitors of ALK.
520 $a This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.
650 0 $a Medicinal chemistry. $3 1253747
650 0 $a Cancer research. $3 1253664
650 0 $a Medical biochemistry. $3 1254555
650 1 4 $a Medicinal Chemistry. $3 668872
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Medical Biochemistry. $3 668897
700 1 $a Waring, Michael J. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 674465
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319759241
776 0 8 $i Printed edition: $z 9783319759258
830 0 $a Topics in Medicinal Chemistry, $x 1862-2461 ; $v 15 $3 1253746
856 4 0 $u https://doi.org/10.1007/978-3-319-75926-5
912 $a ZDB-2-CMS
912 $a ZDB-2-SXC
950 $a Chemistry and Materials Science (SpringerNature-11644)
950 $a Chemistry and Material Science (R0) (SpringerNature-43709)